We are monitoring the impact of COVID-19 on North America Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1113
Share on
Share on

North America Antibodies Market Research Report – Segmented By Product Type, Indication, End User, Application & By Country (U.S., Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2021 to 2026

Pulished: April, 2021
ID: 1113
Pages: 145

The size of the North America Antibodies Market was valued at USD 56.51 Billion in 2020 and estimated to reach USD 101.61 Billion by the end of 2025 with a growing potential of 12.45 % during the forecast period.

North America antibody market is driven by continuous development of innovative products, increased adoption rate to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses owing to population shift and rising longevity, rapid approval by regulatory authorities for breakthrough therapies, and adoption of diagnostic antibodies. Companies are adopting various strategies, like the expansion of product indications to sustain the dynamically growing market.

The high cost of treatment and side effects associated with antibody treatment are the restraints that are affecting the growth of the market.

Based on Product Type, Monoclonal antibodies segment accounts for the highest market share in the market.

Based on End User, the Cancer indication type segment is predicted to account highest market share over the forecast period due to broad range applications of monoclonal antibodies for the treatment of various cancers.

Some of the Prominent Companies leading the North America Antibodies Market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and AbbVie Inc.

This research report has been segmented and sub-segmented into the following categories:

By Product Type:

  • Monoclonal Antibodies
    • Murine
    • Chimeric
    • Humanized
    • Human
  • Polyclonal Antibodies
    • Type I
    • Type II
    • Type III
    • Type IV
    • Type V
    • Type VI
    • Type VII
    • Type VIII
  • Anti-body drug complexes
    • Immunogen Technology
    • Seattle Genetics Technology
    • Immunomedics Technology

By Indication:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End User:

  • Hospitals/Clinics
  • Research institute
  • Diagnostics laboratories

By Application:

  • Medical
  • Experimental
  • Western blot
  • ELISA
  • Radioimmune Assays
  • Immunofluorescence
  • Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

  • The United States
  • Canada
  • Rest of North America

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Abbott Diagnostics (US)                        

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 A.G. Scientific, Inc. (U.S.)                      

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 AbbVie Inc. (U.S.)                  

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. North America Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  2. North America Monoclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  3. North America Polyclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  4. North America Antibody-Drug complexes Market, By Region, From 2020 to 2025 (USD Million)
  5. North America Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  6. North America Cancer Market, By Region, From 2020 to 2025 (USD Million)
  7. North America Auto immune diseases Market, By Region, From 2020 to 2025 (USD Million)
  8. North America infectious diseases Market, By Region, From 2020 to 2025 (USD Million)
  9. North America Cardiovascular diseases Market, By Region, From 2020 to 2025 (USD Million)
  10. North America CNS disorders Market, By Region, From 2020 to 2025 (USD Million)
  11. North America Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  12. North America Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  13. North America Research institute Market, By Region, From 2020 to 2025 (USD Million)
  14. North America Diagnostics laboratories Market, By Region, From 2020 to 2025 (USD Million)
  15. North America Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  16. North America Medical Market, By Region, From 2020 to 2025 (USD Million)
  17. North America Experimental Market, By Region, From 2020 to 2025 (USD Million)
  18. United States Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  19. United States Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  20. United States Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  21. United States Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  22. Canada Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  23. Canada Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  24. Canada Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  25. Canada Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  26. North America Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  27. North America Murine Market, By Region, From 2020 to 2025 (USD Million)
  28. North America Chimeric Market, By Region, From 2020 to 2025 (USD Million)
  29. North America Humanized Market, By Region, From 2020 to 2025 (USD Million)
  30. North America Human Market, By Region, From 2020 to 2025 (USD Million)
  31. United States Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  32. Canada Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  33. North America Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  34. North America Type I Market, By Region, From 2020 to 2025 (USD Million)
  35. North America Type II Market, By Region, From 2020 to 2025 (USD Million)
  36. North America Type III Market, By Region, From 2020 to 2025 (USD Million)
  37. North America Type IV Market, By Region, From 2020 to 2025 (USD Million)
  38. North America Type V Market, By Region, From 2020 to 2025 (USD Million)
  39. North America Type VI Market, By Region, From 2020 to 2025 (USD Million)
  40. North America Type VII Market, By Region, From 2020 to 2025 (USD Million)
  41. North America Type VIII Market, By Region, From 2020 to 2025 (USD Million)
  42. United States Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  43. Canada Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  44. North America Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  45. North America Immunogen Technology Market, By Region, From 2020 to 2025 (USD Million)
  46. North America Seattle Genetics Technology Market, By Region, From 2020 to 2025 (USD Million)
  47. North America Immunomedics technology Market, By Region, From 2020 to 2025 (USD Million)
  48. United States Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  49. Canada Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  50. North America Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  51. North America Western Blot Market, By Region, From 2020 to 2025 (USD Million)
  52. North America ELISA Market, By Region, From 2020 to 2025 (USD Million)
  53. North America Radioimmune Assays Market, By Region, From 2020 to 2025 (USD Million)
  54. North America immunofluorescence Market, By Region, From 2020 to 2025 (USD Million)
  55. United States Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  56. Canada Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample